Historie von Umsatz, Gewinn und Cashflow aus den offiziellen Geschäftsberichten.
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1.
Interaktive Charts und vollständige Abschlüsse ansehen → Bewertungsmodell (DCF) →
| Gewinn- und Verlustrechnung | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gesamtumsatz | $4.8B | $3.7B | $2.2B | $1.8B | $1.0B | $844M | $493M | $220M | $75M | $90M | $47M | $41M | $51M | $47M | $67M | $83M | $100M | $101M | $96M | $51M | $27M |
| Bruttoergebnis | $3.8B | $3.0B | $1.9B | $1.5B | $869M | $704M | $415M | $195M | $73M | $90M | $47M | $41M | $51M | $47M | $67M | $83M | $100M | $101M | $96M | $51M | $27M |
| Bruttomarge % | 79.7% | 81.8% | 85.6% | 83.0% | 83.7% | 83.4% | 84.2% | 88.6% | 97.6% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Betriebsergebnis (EBIT) | $1.0B | $502M | ($177M) | ($282M) | ($785M) | ($709M) | ($828M) | ($939M) | ($815M) | ($500M) | ($425M) | ($296M) | ($405M) | ($93M) | ($129M) | ($55M) | ($44M) | ($48M) | ($28M) | ($93M) | ($40M) |
| Operative Marge % | 20.8% | 13.5% | -7.9% | -15.4% | -75.7% | -83.9% | -168.1% | -427.5% | -1087.6% | -556.2% | -900.3% | -720.3% | -801.0% | -197.0% | -194.0% | -66.2% | -44.0% | -47.9% | -28.9% | -183.1% | -146.7% |
| Jahresüberschuss | $807M | $314M | ($278M) | ($440M) | ($1.1B) | ($853M) | ($858M) | ($886M) | ($761M) | ($491M) | ($410M) | ($290M) | ($360M) | ($89M) | ($106M) | ($58M) | ($44M) | ($48M) | ($26M) | ($85M) | ($35M) |
| Nettomarge % | 16.8% | 8.5% | -12.4% | -24.1% | -109.0% | -101.0% | -174.2% | -403.2% | -1016.6% | -546.0% | -869.6% | -705.8% | -712.8% | -189.2% | -158.9% | -69.7% | -43.5% | -47.3% | -27.3% | -167.9% | -128.5% |
| EBITDA | — | $631M | ($179M) | ($258M) | ($927M) | ($662M) | ($736M) | ($885M) | ($754M) | ($487M) | ($409M) | ($277M) | ($172M) | ($83M) | ($52M) | ($50M) | ($38M) | ($41M) | ($19M) | ($75M) | ($36M) |
| Ergebnis je Aktie (EPS) | $5.90 | $2.33 | $-2.18 | $-3.52 | $-9.30 | $-7.20 | $-7.46 | $-8.11 | $-7.57 | $-5.42 | $-4.79 | $-3.45 | $-4.85 | $-1.45 | $-2.11 | $-1.36 | $-1.04 | $-1.14 | $-0.64 | $-2.21 | $-1.09 |
| Ausstehende Aktien (Mio.) | — | 135M | 128M | 125M | 122M | 118M | 115M | 109M | 101M | 91M | 86M | 84M | 74M | 62M | 50M | 42M | 42M | 42M | 41M | 39M | 32M |
Quelle: veröffentlichte Unternehmensberichte (SEC). Bitte prüfen Sie die Zahlen vor Verwendung auf SEC EDGAR.
Bilanzen, Cashflow-Rechnungen, Quartalsdaten und alle Kennzahlen finden Sie im interaktiven Viewer für ALNY. /companies/us/ALNY
Die Informationen auf dieser Website dienen ausschließlich Bildungs- und Informationszwecken und stellen keine Anlageberatung dar. Es werden keine Kursziele und keine Anlageurteile veröffentlicht.
About TickerBase · Data methodology & sources · Privacy · Terms